AMPLIFICATION OF c-MYC AND MLL GENES
AS A MARKER OF CLONAL CELL PROGRESSION
IN PATIENTS WITH MYELOID MALIGNANCY
AND TRISOMY OF CHROMOSOMES 8 OR 11
Angelova S1,*, Jordanova M2, Spassov B1, Shivarov V1, Simeonova M3,
Christov I4, Angelova P3, Alexandrova K5, Stoimenov A1, Nikolova V1,
Dimova I6, Ganeva P1, Tzvetkov N4, Hadjiev E5, Toshkov S1
*Corresponding Author: Svetlana Angelova, Biologist, Laboratory of Cytogenetics and Molecular Biology,
National Specialized Hospital for Active Therapy of Hematological Diseases, 6, «Plovdivsko pole», Sofia, 1756,
Bulgaria; Tel.: +35929701133; Fax : +35929701107; E-mail: sv_angelru@abv.bg
page: 17
download article in pdf format
|
|
Abstract
Gene amplification (amp) is one of the basic
mechanisms connected with overexpression of oncogenes.
The c-MYC (located in 8q24) and MLL (located
in 11q23) are the most often over represented genes
that lead to a rapid proliferation of the affected cell
clone in patients with myeloid neoplasms. Assessment
of the level of amp c-MYC or amp MLL in the cases
with trisomy 8 (+8) or trisomy 11 (+11) and myeloid
malignances is necessary for a more precise estimation
of the disease progression.
A total of 26 patients with acute myeloid leukemia
(AML) and myelodysplastic syndromes (MDS) were
included in the study: 18 with +8, six with +11 and
two with complex karyotypes suspected of the partial
trisomy. Routine cytogenetic analysis and fluorescent
in situ hybridization (FISH) were applied to indicate
the chromosome alterations and genes amp in the bone
marrow cells.
Amp c-MYC was observed in 12 from 18 (66.7%)
patients with +8. All the patients with +11 demonstrated
a different level of amp MLL. In most of the cases
with MDS (9/10), the coincidence of the +8 or +11
with amp c-MYC or amp MLL, respectively, leads to
transformation to AML and/or short overall survival.
Our data suggest that amp c-MYC and amp MLL develop
in conformity with +8 and +11, especially in
cases with progressive deviations in the karyotype as
an aggressive expansion of an aberrant cell clone and
appearance of additional chromosome anomalies.
|
|
|
|
 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
